(HealthDay News) — Neoadjuvant semaglutide before metabolic and bariatric surgery (MBS) is not beneficial in terms of weight loss, according to a research letter published online in JAMA Surgery.

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

Wegovy contains the same main ingredient as Ozempic, semaglutide, and is FDA-approved for weight loss in people with obesity or who are overweight with at least one weight-related condition. It is ...

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...

DUBLIN--(BUSINESS WIRE)--The "Liraglutide ... of type 2 diabetes and obesity. These drugs are useful components of multimodal therapy approaches because they boost weight loss efforts in addition ...

People using weight-loss injections are being warned of potential side effects that could impact their ability to drive ...

“This study showed neoadjuvant semaglutide did not confer benefits for weight loss, diabetes remission, or MBS safety,” the authors write. Several authors disclosed ties to the ...

Very few people are currently being prescribed drugs for weight loss on the NHS in Scotland, research by BBC Scotland News ...

A WOMAN has revealed the bizarre transformation that took place after going on weight loss jabs – and it wasn’t her body. Amy ...

He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed ...

A WOMAN has left TikTok users divided after claiming to have lost seven stone after taking weight loss drug Mounjaro for 11 ...